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Background: Secreted luciferases are highly useful bioluminescent reporters for cell-based assays and drug
discovery. A variety of secreted luciferases from marine organisms have been described that harbor an N-terminal
signal peptide for release along the classical secretory pathway. Here, we have characterized the secretion of
Gaussia luciferase in more detail.
Results: We describe three basic mechanisms by which GLUC can be released from cells: first, classical secretion by
virtue of the N-terminal signal peptide; second, internal signal peptide-mediated secretion and third, non-conventional
secretion in the absence of an N-terminal signal peptide. Non-conventional release of dNGLUC is not stress-induced,
does not require autophagy and can be enhanced by growth factor stimulation. Furthermore, we have identified the
golgi-associated, gamma adaptin ear containing, ARF binding protein 1 (GGA1) as a suppressor of release of dNGLUC.
Conclusions: Due to its secretion via multiple secretion pathways GLUC can find multiple applications as a research
tool to study classical and non-conventional secretion. As GLUC can also be released from a reporter construct by
internal signal peptide-mediated secretion it can be incorporated in a novel bicistronic secretion system.
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Secreted luciferases are versatile tools to investigate
cell-based processes based on their high sensitivity, lack
of toxicity, small size, wide dynamic range for quantitation
and potential for multiplexing. The first secreted luciferase
identified was isolated from the marine ostracod crust-
acean, Cypridina hilgendorfii, now named Vargula hilgen-
dorfii [1]. Later, secreted luciferases were identified in the
marine copepod crustaceans Gaussia princeps [2], Metridia
longa [3], Metridia pacifica [4] and, more recently, from
copepods of the Heterorhabdidae, Lucicutiidae and Augap-
tiloidae families [5,6]. With the exception of Vargula lucif-
erase, that uses luciferin, all secreted luciferases utilize the
substrate coelenterazine to convert light into a biolumin-
escent signal. Recently, a small, secreted luciferase termed* Correspondence: r.ketteler@ucl.ac.uk
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unless otherwise stated.Nanoluc engineered from a deep-sea shrimp luciferase
has been developed that utilizes furimazine as substrate in
an ATP-independent reaction [7].
One hallmark of secreted luciferases is their flash-type
kinetics which has limited the use in drug discovery
high-throughput screening applications. This hurdle has
been overcome by engineering of Gaussia luciferase with
glow-type characteristics [8-10]. Gaussia luciferase has
been used to measure various cellular processes in cell-
based assays as well as in vivo [11]. A split-GLUC system
has been developed [12,13] and used for imaging of
receptor-ligand interactions [14], virus-host protein in-
teractions [15] and oligomer formation of amyloid beta
peptide [16]. A highly useful property of Gaussia lucifer-
ase is its stability in body fluids such as blood and urine.
This has facilitated the development of in vivo sensors
for analysis of tumour growth [17] and caspase activa-
tion [18], among others. Secretion of Gaussia luciferase
is mediated by a conventional N-terminal signal peptide.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lularly retained version is possible [19], facilitating the
development of intracellular biosensors. Two modifica-
tions are necessary for the development of such “lucifer-
ase release assays”: one is the deletion of the N-terminal
signal peptide (dNGLUC) and the second is the attach-
ment of an anchor to dNGLUC, either by linkage to the
actin cytoskeleton or other intracellular retained pro-
teins [18,19]. The first luciferase release assay was used
to monitor caspase 8 and 9 activation [19] and autoph-
agy protease ATG4B activation [20]. Later, biosensors
for caspase 3 [21], HCV protease [22] and caspase 1 [18]
have been developed, all based on the proteolytic cleav-
age of a peptide sequence that is inserted between Gaus-
sia luciferase and the anchor molecule, thus resulting in
liberation and export of the luciferase from cells. The
non-invasive nature of the luciferase release assay makes
it a good assay for high-throughput screening and drug
discovery applications and has been successfully used to
identify molecular regulators of apoptosis and autophagy
[20,23-26]. However the mechanism of the non-conventional
secretion that underlies the luciferase release assay is
poorly understood. In this study, we have identified mo-
lecular determinants that regulate non-conventional secre-
tion of dNGLUC and have studied the role of autophagy in
this process.
Results
Non-conventional release of Gaussia luciferase
This study examines the suitability of wild-type GLUC
and dNGLUC, a deletion mutant without N-terminal sig-
nal peptide, as reporter systems to study protein secretion.
Multiple tagged versions of GLUC and dNGLUC were
generated as shown in Figure 1A. These include green
fluorescent protein (GFP)-tagged versions of GLUC and
dNGLUC as well as β − actin tagged versions. First, it was
confirmed that dNGLUC is efficiently released from cells
in the absence of a signal peptide, whereas β-actin-tagged
dNGLUC is retained inside cells (Figure 1B). One possible
explanation is that dNGLUC harbors a new N-terminal
secretion signal that would allow export from the cells. In
order to test this hypothesis, dNGLUC was tagged with
GFP to generate GFP-dNGLUC. GFP-dNGLUC was re-
leased from cells to a similar extent as dNGLUC and re-
lease for both dNGLUC and GFP-dNGLUC was sensitive
to treatment with Brefeldin A, thus suggesting that ER-
Golgi trafficking is required (Figure 1B,C).
GFP- and β-actin-tagged versions of wild-type GLUC
with an internal signal peptide between the two open
reading frames as well as wt GLUC were also tested for
release of luciferase activity from cells. As expected,
wild-type GLUC was released at high levels from cells.
In addition, GFP-tagged GLUC and β-actin-tagged
GLUC were also secreted at moderate levels from cells(Figure 1D), despite the absence of an N-terminal signal
peptide. Secretion of GFP-SPGLUC and β-actin-SPGLUC
was sensitive to treatment with Brefeldin A (Figure 1E).
Unlike β-actin-dNGLUC without internal signal pep-
tide, β-actin-SPGLUC with internal signal peptide was
not retained in cells. One hypothesis is that an internal
signal peptide is sufficient to mediate release of the down-
stream peptide sequence.
Bicistronic reporter gene expression
It has been shown before that internal signal peptides
have the potential to result in secretion of the down-
stream gene and can be cleaved by signal peptidase [27].
To examine whether the internal signal peptide in GFP-
SPGLUC is cleavable, we performed immuno-blotting
using a polyclonal antibody raised against the C-terminal
part of GLUC. In untreated 293 T cells transfected with
GLUC, we observed an expected band at ~20 kDa that
increased in intensity upon treatment with Brefeldin A,
consistent with accumulation of GLUC inside cells upon
blockage of release (Figure 2A). For GFP-SPGLUC and
β-actin-SPGLUC multiple bands were observed including
a band at 47 kDa and 62 kDa, respectively, that corre-
sponds to the length of the full-length protein, as well as
a band at 20 kDa that corresponds in size to wild-type
GLUC. Upon treatment with Brefeldin A, the 20 kDa
band increased in intensity, while the bands correspond-
ing to full-length GFP-SPGLUC or β-actin-SPGLUC did
not change in intensity. Therefore, we proposed that
GFP-SPGLUC and β-actin-SPGLUC are cleaved at the site
of the signal peptide and the cleaved GLUC but not the
full-length construct is released from cells. To test this
hypothesis, we enriched supernatants from serum-free
media and performed immuno-blotting of cell lysates
and enriched supernatants in the presence or absence of
Brefeldin A (Figure 2B). From cells transfected with
GLUC, a strong band at ~20 kDa was observed in super-
natants that was reduced upon treatment with Brefeldin
A. Similarly, from cells transfected with GFP-SPGLUC, a
single band at ~20 kDa was observed that was significantly
reduced in supernatants and increased in cell lysates upon
treatment with Brefeldin A (Figure 2B). No band corre-
sponding to full length GFP-SPGLUC was observed in the
supernatant, indicating the protein needs to be cleaved for
secretion. We therefore conclude that the strong GFP-
SPGLUC secretion is mediated by cleavage of an internal
signal peptide.
GLUC is heat-stable
We noted that GLUC activity in supernatants was very
stable and that the supernatants could be stored at room
temperature for several days without apparent loss of
luciferase activity. GLUC and dNGLUC activities were
Figure 1 Three types of secretion for Gaussia luciferase activity. A, Constructs used in this study are wild-type Gaussia luciferase (GLUC), an
N-terminal deletion mutant that has no signal peptide (dNGLUC), GFP-tagged GLUC with an internal signal peptide (GFP-SPGLUC), GFP-tagged
dNGLUC and β-actin-tagged GLUC with and without an internal signal peptide (Actin-SPGLUC, Actin-dNGLUC). The signal peptide is shown as a
black box, GLUC without signal peptide is shown in white, GFP as a striped box and β-actin as a grey box. B, 293 T cells were transfected with
dNGLUC, GFP-dNGLUC and β-actin-dNGLUC, supernatants and cell lysates were collected after 24 h and analyzed for luciferase activity. GLUC
activity was measured as described in Methods. C, 293 T cells were transfected with dNGLUC and GFP-dNGLUC and cultured for 24 h prior to a
media change. Fresh medium containing DMSO or 10 μg/mL Brefeldin A was added to the cells and supernatants were collected after 2 h for
analysis of luciferase activity. D, 293 T cells were transfected with GLUC, GFP-SPGLUC and β-actin-SPGLUC and analyzed for luciferase activity in su-
pernatants after 24 h. E, 293 T cells were transfected with GFP-SPGLUC and βActin-SPGLUC, treated with Brefeldin A and supernatants were col-
lected and analyzed for luciferase activity as described. B-D, Shown is the mean of three independent experiments with standard error bars. R.L.U.
– relative light units, SN – supernatant.
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PBS, and were absent following treatment with 1% SDS
(Figure 3A,B). Incubation of supernatants at 95°C for
5 min did not result in a significant reduction of GLUC
activity (Figure 3A,B). In order to test whether GLUC
and dNGLUC are stable at elevated temperatures, thus
facilitating the use in time kinetic measurements at
physiological temperatures, the half-life of GLUC and
dNGLUC at 37°C was determined in a timecourse ex-
periment (Figure 3C,D). GLUC and dNGLUC activity
did not show any loss of activity even after incubation
for 5 days at 37°C. Thus, GLUC and dNGLUC are very
stable reporter proteins that can be used for kinetic
measurements of protein expression and secretion at
physiological temperatures.Non-conventional GLUC release is not stress-induced and
does not require autophagy
Recently, it has been observed that autophagy can contribute
to secretion of cytoplasmic proteins by a non-conventional
secretion route [28-31]. In order to determine whether au-
tophagy is involved in the release of dNGLUC, 293 T cells
were treated with various agents that are known to induce
or inhibit autophagy (Table 1, Figure 4A), as well as
Brefeldin A and digitoxin as autophagy independent
controls. Inducers of autophagy such as rapamycin did
not increase secretion of dNGLUC. Blocking autophago-
lysosomal fusion by treatment with chloroquine had only a
minor effect on release of dNGLUC from cells (Figure 4A).
None of the treatments except digitoxin had a significant
effect on overall cell viability (Table 1), thus supporting the
Figure 2 Bicistronic expression system for release of Gaussia luciferase activity. A, whole cell lysates from transfected 293 T cells described
in Figure 1E were subjected to 10% PAGE and subsequent immunoblotting using a rabbit anti-GLUC antibody. Bands corresponding to GLUC are
indicated by an arrowhead and bands corresponding to intact GFP-SPGLUC and β-actin-SPGLUC are indicated by asterisks. B, 293 T cells transfected
with GLUC or GFP-SPGLUC were analyzed for GLUC activity in cell lysates and supernatants by immuno-blotting with anti-GLUC antibody. Supernatants
and cell lysates were collected from the same well. Supernatants were enriched as described in Methods. Cell lysates and supernatants were resolved
by PAGE and bands were detected with anti-GLUC antibody. Bands corresponding to GLUC are indicated by an arrowhead and bands corresponding
to intact GFP-SPGLUC are indicated by an asterisk. Experiments have been performed three times and shown are representative blots. SN
– supernatant.
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somal processes has an effect on dNGLUC release from
cells.
In order to test whether cells defective in autophagy
would exhibit dNGLUC release, murine embryonic fi-
broblasts from an inducible ATG5 knockout mouse [39]
were transduced with dNGLUC and treated with doxy-
cycline for up to 3 days. ATG5 is essential for LC3 lipi-
dation and the formation of the autophagic membrane.
After 3 days of treatment, autophagy was defective in
these cells as indicated by an absence of the lipidated
form of LC3, LC3-II (Figure 4B) and an absence of ATG5
(Figure 4C). Release of dNGLUC from autophagy-
defective cells was not decreased (Figure 4D), indicat-
ing that autophagy is not required for the release of
dNGLUC.Release of Gaussia luciferase can be enhanced by
stimulation with growth factors
In order to assess whether Gaussia luciferase can be used
for kinetic measurements of rapid cellular processes, the
kinetics of dNGLUC release from cells were determined.
The amount of dNGLUC in cell supernatants at various
time points after a PBS wash and media change was mea-
sured. dNGLUC is a very sensitive reporter gene and re-
lease into supernatants was detected as early as 5 min
after media change (Figure 5A). The amount of luciferase
activity in supernatants increased in a linear manner over
time up to 2 h, indicating a steady-state release into super-
natants. No sign of cell death or damage was observed,
even at later time points, that might explain release. In
contrast, treatment with cytotoxic agents typically reduced
the amount of dNGLUC detected in supernatants, sug-
gesting that dNGLUC release requires cell vitality (see
Figure 4A).In order to test whether release of dNGLUC from cells
could be controlled by growth-promoting factors, lucif-
erase release from cells expressing dNGLUC in serum-
free media were compared to cells in complete media. A
significant reduction in dNGLUC release was observed
compared to that of cells cultured in complete media
(Figure 5B). Next, the kinetics of release of dNGLUC in
serum-free and serum-containing media was explored.
As can be seen in Figure 5C, serum strongly enhanced
release of dNGLUC within 1 h of addition to the culture,
indicating an early response to growth factors. To deter-
mine whether this effect could be attributable to growth
factors as opposed to other serum constituents, COS-7
cells expressing dNGLUC were treated with 100 ng/ml
EGF for 2 h and release of dNGLUC into supernatants
was analyzed. Epidermal Growth Factor alone strongly stim-
ulated release of dNGLUC into supernatants (Figure 5D),
indicating that release of dNGLUC is responsive to growth
factor treatment.
Non-conventional GLUC release is suppressed by GGA1
In order to identify proteins that regulate the non-
conventional secretion of GLUC, shRNA-mediated knock-
down of candidate proteins involved in Golgi trafficking
was examined. shRNA-mediated knockdown of a Golgi-
associated protein, Golgin-Gamma-ear-Adaptin (GGA)
1 (Figure 6A) was found to significantly enhance release
of dNGLUC (Figure 6B). Furthermore, overexpression
of GGA1 resulted in a strong reduction of dNGLUC re-
lease (Figure 6C). As a control, the release of another
unconventionally secreted protein, Fibroblast Growth
Factor (FGF)-2, was investigated. Release of FGF2 from
293 T cells was not affected by shRNA-mediated knock-
down of GGA1 (Figure 6D), in accordance with the notion
that FGF2 secretion is insensitive to treatment with Brefeldin
A and requires a plasma membrane transporter [40].
Figure 3 GLUC and dNGLUC activities are heat-stable. A, B, 293 T cells were transfected with GLUC or dNGLUC and supernatants
were collected after 24 h. 10 μL of supernatant were mixed in 90 μL of PBS, or PBS/1% SDS at room temperature or in 90 μl PBS
incubated at 95°C for 5 min before analysis. C, D Supernatants from cells expressing GLUC or dNGLUC were incubated at 37°C for the
indicated time points prior to analysis in a plate reader. A-D, shown is the mean plus standard deviations of three experiments.
R.L.U. – relative light units, SN - supernatant.
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knockdown of GGA1 could be reversed by transfection
of a Flag-tagged GGA1 construct refractory to knockdown
(GGA1m; Figure 6E). We therefore conclude that GGA1
is an endogenous inhibitor of dNGLUC release.Table 1 Effect of autophagy modulators on dNGLUC secretion




Brefeldin A Inhibition of Golgi trafficking [32]
Digitoxin Inhibition of sodium-potassium ATPase [33
Autophagy inhibitors
Chloroquine Prevention of lysosome acidification and ly
autophagosome fusion [34]
Autophagy activators
Trifluoperazine Dopamine antagonist [34]
Rapamycin Inhibition of mTOR [35]
Tamoxifen Inhibition of mTOR signaling via increased ce
Thenoyltrifluoro- actetone Inhibition of mitochondrial electron transpDiscussion
Gaussia luciferase activity can be released from cells by
three distinct mechanisms: 1) classical N-terminal signal
peptide mediated secretion (GLUC); 2) internal signal pep-




57.8 ± 4.1 1.0
63.9 ± 1.1 1.0
9.1 ± 0.9 1.0
] 8.4 ± 0.9 0.4
sosome 44.8 ± 5.5 0.7
58.1 ± 3.1 1.2
51.8 ± 5.1 0.8
ramide levels [36,37] 38.1 ± 3.6 0.8
ort [38] 61.1 ± 3.3 0.9
Figure 4 Release of Gaussia luciferase does not require autophagy. A, 293 T cells were treated with 10 μM of digitoxin (Dig), chloroquine
(CQ), Trifluorperazine (TFP), rapamycin (Rap), tamoxifen (Tam), or theonyltrifluoracetone (TTFA), 10 μg/mL Brefeldin A, DMSO or left untreated (NT)
and analyzed for luciferase activity in supernatants (*P < 0.05; **P < 0.01; ***P < 0.001). B, embryonic fibroblasts from ATG5 inducible knockout
mice were transduced with dNGLUC. ATG5 knockout was induced using 1 μg/mL of doxycycline. Cells and supernatants were collected on three
consecutive days after induction. Cells were washed and incubated in fresh medium for an additional 2 h before collection of supernatant. The
efficiency of ATG5 knockout was verified by immunoblotting with detetction of LC3 (B), β-actin, and ATG5 (C). D, Luciferase activity in the
correspondent supernatants was measured using the Perkin Elmer Envision II at the indicated time points. A, B, shown is the mean plus standard
deviation of three experiments. Significances were calculated with a two-sided paired t-test. R.L.U. – relative light units, SN - supernatant.
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peptide (dNGLUC). While assays based on conventional
secretion of Gaussia luciferase have been previously de-
scribed [41], the data presented here support two novel
applications of Gaussia luciferase: (1) with the use of an
internal signal peptide to monitor bicistronic gene ex-
pression and secretion and (2) use as a reporter to study
non-conventional secretion mechanisms.
One advantage of secreted luciferases is their potential
for deployment in multiplexed reporter assays. However,
one limitation for multiplexing is the availability of expres-
sion cassettes for multiple reporter genes. To circumvent
this problem, bicistronic expression systems are available
such as those based on internal ribosomal entry sites
(IRES) or self-cleaving peptides (e.g. the picornavirus 2A
sequence [42]). However, IRES-based systems can result
in inefficient expression of the downstream gene, and P2Aself-cleaving peptides leave both a C-terminal extension
on the upstream gene product, and an N-terminal proline
on the downstream product. It has been shown that in the
presence of an N-terminal signal peptide at the front of
two sequential proteins, an internal signal sequence can
function to export the two proteins from the cell [27]. The
internal signal sequence can function either as a transfer
signal resulting in export of the downstream peptide or al-
ternatively as a stop-transfer signal resulting in membrane
anchoring of the full peptide sequence. The bicistronic ex-
pression system proposed here based on GFP fused to
Gaussia luciferase results in efficient export of the peptide
downstream of the signal peptide. Interestingly, the Gaussia
luciferase internal signal sequence functions in the ab-
sence of an N-terminal signal sequence as demonstrated
for GFP-SPGLUC and β-actin-SPGLUC. A systematic com-
parison of signal sequence strength has previously shown
Figure 5 Secretion of dNGLUC is induced by growth factor stimulation. A, 293 T cells were transfected with dNGLUC and cultured
overnight. Cells were washed once in PBS and fresh media was added. Supernatants were collected at the indicated time points prior to analysis
on a PerkinElmer Envision multilabel plate reader. B, C, 293 T cells expressing dNGLUC were cultured for 24 h and then starved in 0.1% FCS
overnight. Media containing serum (full line) or no serum (dotted line) was added back to the cells and luciferase activity in supernatants was
measured after 4 h (B) or at the indicated time points (C) using a PerkinElmer Envision II plate reader. Shown is the mean of 5 independent
transfections with standard deviation. D, COS-7 cells were transiently transfected with pEAK12-dNGLUC using calcium phosphate precipitation,
cultured for 24 h and then starved overnight in 0.1% FCS. Cells were then stimulated with 100 ng/mL EGF at 37°C for 2 h and supernatants were
harvested. C-D, shown is the mean of three experiments plus standard deviations. R.L.U. – relative light units, SN - supernatant.
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most efficient secretory signals known [43], which may ex-
plain the effective export of proteins even when the signal
sequence is placed between two reporter proteins. Ourresults indicate GLUC should have utility for bicistronic
reporter gene expression and secretion.
Protein secretion is a complex process that involves
intra-cellular trafficking steps and post-translational
Figure 6 Release of Gaussia luciferase is suppressed by GGA1. A, To test efficiency of shRNA mediated GGA knockdown 293 T cells
expressing Flag-tagged GGA1 were co-transfected with pLKO control vector or pLKO shGGA. Cell lysates were resolved on 10% PAGE and transferred
to PVDF membranes. The blots were probed with anti-Flag M2 or anti-β-actin antibody. B, 293 T cells were co-transfected with dNGLUC and
the shRNA vectors pLKO (control) or pLKO shGGA and cultured for 72 h. Supernatants were harvested and analyzed for Gaussia luciferase activity
using a PerkinElmer TopCount. C, 293 T cells were co-transfected with dNGLUC and an expression vector for GFP or GGA1 and cultured for 24 h prior
to analysis of GLUC activity in supernatants as in A. D, FGF2 was transfected into 293 T cells together with a control vector (pLKO) or an shRNA vector
targeting GGA1. FGF2 secretion into supernatants was measured using an ELISA kit (R&D Systems) after 24 h. E, 293 T cells expressing dNGLUC were
co-transfected with pLKO vector control or shGGA and wild-type Flag-GGA1 or a mutant version of GGA1 that is refractory to shRNA mediated
knockdown by shGGA (GGA1m). Supernatants were harvested after 48 h and analysed for GLUC activity as previously described. B-E, shown are
the results from three independent experiments plus standard deviation. R.L.U. – relative light units, SN - supernatant.
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tion involves translocation of the nascent polypeptide
from the ribosome to the lumenal endoplasmatic reticulum
(ER) followed by vesicular transport through the Golgi.
This type of secretion is initiated by interaction of a
hydrophobic N-terminal signal sequence on the polypep-
tide with the signal recognition particle. Some proteins,
however, lack an N-terminal signal peptide and are se-
creted by a non-conventional secretion that is insensitive
to treatment with inhibitors of ER/Golgi trafficking such
as Brefeldin A [44,45]. Proteins known to undergo
non-conventional secretion include interleukin (IL) -1α
and -1β, fibroblast growth factor (FGF) 1 and 2, HIV tat,transglutaminases and galectins, among others. In some
cases, including those of HIV tat, FGF-2 and cellular
transglutaminase, the export is constitutive, whereas in
other cases secretion is initiated by a regulated event, such
as the cleavage of interleukins 1α and 1β by caspase-1.
Multiple mechanisms for non-conventional secretion have
been identified, including lysosomal secretion, plasma
membrane shedding, exosomal release, as well as secre-
tion through plasma membrane resident transporters [46].
In general, non-conventional secretion is poorly under-
stood and should benefit from the application of novel
tools that permit the use of unbiased approaches such as
high-throughput screening technologies. We present here
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study non-conventional secretion.
Recently, an involvement of autophagy in non-
conventional secretion has been described in yeast,
Drosophila, mammals and plants [28-31,47]. We have
shown that cellular stress responses and autophagy are
not involved in dNGLUC release, because the same
amount of dNGLUC was released from ATG5−/− null
cells as was released from control cells. In addition,
treatment with autophagy inducers or inhibitors had
no effect on release of dNGLUC. The underlying mecha-
nisms of this type of secretion are worthy of further inves-
tigation, firstly because the process is unusual and may
expose new aspects of general cell biology, and secondly
because such an understanding would enhance the de-
velopment of reporter systems based on this type of
secretion.
In this study we have also shown that GGA1 suppresses
release of dNGLUC from cells. GGAs are a family of
monomeric clathrin adaptors that mediate the sorting of
transmembrane cargo from the trans-Golgi network to
late endosomes [48]. GGA1 can directly interact with cla-
thrin [49-51], AP1 [52,53], ARF [54], Rabaptin-5 [55,56]
and with a variety of cargo molecules [57], and is required
for sorting of the lysosomal targeting receptor, mannose-
6-phosphate receptor [48,52]. It has also been observed
that overexpression of GGA3 inhibits retrovirus assembly
[58], and that the molecule interacts with TSG101, an
ubiquitin-binding component of the multivesicular body
that is a key regulator of HIV budding. In addition, GGAs
have been implicated in trafficking and processing of APP
[59-62] have been found to bind to β-secretase [44,63,64]
and appear to restrain Aβ secretion, as indicated by the
enhanced secretion observed following siRNA mediated
knockdown of GGA1. Here, we have observed suppres-
sion of secretion of dNGLUC by GGA1.
In principle GGA1 might suppress release of dNGLUC
by interfering with lysosomal sorting. In this scenario
dNGLUC might be sorted in large measure to the lyso-
some and consequently, suppression of lysosomal target-
ing would result in a net increase of flux through other
trafficking routes. However, lysosomal inhibitors such as
chloroquine had no effect on release of dNGLUC, dimin-
ishing the attractiveness of this hypothesis.Conclusions
In summary, we present here a novel type of secretion
that occurs in the absence of a signal peptide, can ferry
diverse cargo to the extracellular space, is enhanced by
growth factor stimulation and does not require autophagy.
In the future, it will be desirable to address the molecular
mechanisms of this type of secretion in more detail. The
secreted luciferase presented here should be an excellenttool to expose additional features of the mechanism
using high-throughput screening technologies.
Methods
Plasmids and constructs
pEAK12-dNGLUC, GFP-dNGLUC and Actin-LC3-dNGLUC
have been described previously. GFP-SPGLUC and
Actin-SPGLUC were generated by inserting the wild-type
GLUC sequence into pEAK12-GFP and pEAK12-Actin-
LC3-dNGLUC between EcoRI and NotI restriction sites.
GGA1 was amplified by PCR using primers 5’-GACG
AATTCATGGAGCCCGCGATGG-3’ and 5’- GACGCGG
CCGCCTAGAGGCTACCCCAGG-3’ and inserted via
EcoRI/NotI into pEAK13-Flag. A GGA1 mutant that is
refractory to siRNA treatment was generated by overlap
extension PCR using the following internal primers:
cctccaAgAccTaaAaatgtgA and ccacatttttaggtcttggagg.
pLKO shRNA vectors were obtained from SigmaAldrich.
The sequence for knockdown of GGA1 was: CGGCCG
AAGAATGTGATCTTTGAA.
Cell culture
293 T and COS-7 cells were cultured in Dulbecco’s modi-
fied essential media (DMEM, Gibco) supplemented with
10% fetal bovine serum (Sigma-Aldrich), 1% GlutaMAX
(Gibco) and 1% penicillin/streptomycin (Gibco). Doxycycline-
inducible ATG5−/− murine embryonic fibroblasts (MEF)
[39] were obtained from Dr. Noboru Mizushima (Tokyo
Dental Institute) and were cultured in DMEM (Gibco) sup-
plemented with 1% GlutaMAX, 1% penicillin/streptomycin,
1% sodium pyruvate (PAA) and 10% FBS (Sigma-Aldrich).
Cells were induced with 1 μg/ml doxycycline (SigmaAldrich)
for the indicated time points.
Small molecule compound treatment
All compounds were obtained from Sigma-Aldrich and
dissolved in DMSO as 10 mM stock solutions unless
otherwise indicated. Brefeldin A was purchased as a solu-
tion (10 mg/ml) from Sigma-Aldrich. Chloroquine (Sigma-
Aldrich) was kept as a 25 mM stock solution in water.
293 T cells expressing dNGLUC were washed once with
culture medium before addition of compounds in complete
DMEM. Concentrations and time of incubation are detailed
in the Figure legends. Epidermal Growth Factor (EGF)
was obtained from PeproTech. COS-7 cells were starved
overnight in 0.1% serum and stimulated with 100 ng/ml
EGF at 37°C.
Transfection and retroviral transduction
293 T cells were transfected with expression plasmids
using calcium phosphate precipitation as described [65]
or Lipofectamine 2000 (Invitrogen) at 200 ng/well in a 96-
well plate. DNA was mixed with 0.5 ml Lipofectamine in
Luft et al. BMC Biochemistry 2014, 15:14 Page 10 of 12
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room temperature before addition to cells.
To express dNGLUC in MEFs, pMOWSdSV-dNGLUC
was used for retroviral transduction. Retroviral stocks were
prepared by transient transfection of 293 T cells. A solution
consisting of 1 mL DMEM, 75 μL of 1 mg/mL polyethyle-
nimine, 5 μg of each of the viral helper plasmids VSV-G
and Gag Pol and 20 μg of pMOWSdSV-dNGLUC was
prepared, incubated for 20 minutes and added to a 10 cm
plate of 293 T cells at 60% confluency. The following day
the culture medium was replaced with 7 mL of fresh cul-
ture medium. The resulting virus-containing supernatant
was collected two days after transfection and filtered
through a 0.45 μm cellulose acetate filter. Upon addition
of polybrene to a final concentration of 1 μg/mL, the virus
solution was added to a 6 cm plate of MEFs at 70% con-
fluency. After 24 h the solution was exchanged with regu-
lar culture media.
Protein concentration
293 T cells were cultured in serum-free medium overnight,
supernatants were collected, filtered through 0.45 μm filter
and 500 μl portions were loaded onto Amicon Ultra
spin prep columns (Millipore) with a cut-off of 3000 Da.
Samples were spun at 14,000 rpm and 4°C for 60 min
prior to elution of concentrated protein samples. Samples
were then mixed with sample buffer and analyzed by
immuno-blotting. The volume was concentrated ~10-fold.
Luciferase assay
Native Coelenterazine (Biotium) was dissolved at a con-
centration of 1 mg/mL in acidified Methanol. An assay
buffer was prepared by mixing the coelenterazine solu-
tion 1:100 with Gaussia luciferase buffer (0.1% disodium
phosphate, 5% glycerol, 150 mM sodium bromide, 1 mM
EDTA, 25 mM Tris–HCl pH8 and 2 mM ascorbic acid).
10 μL of supernatants were transferred to black 96-well
plates and mixed with 90 μL assay buffer prior to ana-
lysis of luciferase activity in a PerkinElmer Envision II
plate photometer.
Cell viability assay
An assay solution was prepared by diluting Cell Counting
Kit-8 stock solution (Sigma) 1:50 in PBS. Culture medium
was aspirated from 293 T cells in 96 well plates and re-
placed with 100 μL of the assay solution. After 2 h incuba-
tion at 37°C the absorbance at 450 nm was measured with
a PerkinElmer Envision II.
Elisa
Fibroblast Growth Factor 2 (FGF2) in supernatants was
measured with a R&D Systems ELISA kit according to
the manufacturer’s instructions.Immuno-blotting
293 T cells were lysed in NP40 lysis buffer (50 mM
Tris–HCl pH8, 0.5% NP40, 0.1% EDTA, 10% glycerol
and protease inhibitors), mixed with 2× SDS sample buf-
fer and loaded onto 10% PAGE pre-cast gels (BioRad).
Proteins were transferred to a PVDF membrane and
subsequently blocked for 1 to 2 h in blocking solution
(5% skimmed milk and 0.1% Tween in PBS). Proteins of
interest were probed with primary antibodies overnight
at 4°C in blocking solution. HRP-conjugated secondary
antibody incubation was conducted for 1 h at room
temperature in blocking solution. Antibody bound pro-
teins were detected using ECL reagents. The following
antibodies were used: anti-GLUC (Ketteler et al. [19,20],
anti-Flag M2 (Sigma-Aldrich), anti-β-Actin (Abcam),
anti-LC3 (Sigma-Aldrich), anti-ATG5 (Nanotools), HRP
anti-mouse (Santa-Cruz) and HRP anti-rabbit (Santa-Cruz).
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